Search Results
Dr. DiNardo on the FDA Approval of Oral Azacitidine in AML
Courtney D. DiNardo, MD, MSCE, on the Approval of a Venetoclax Combo in Older Adults with AML
Dr. Mims on FDA Approval of Ivosidenib in Patients With AML
Dr. DiNardo on the Efficacy of Venetoclax Combination Therapies in AML
Rationale of OMNIVERSE: oral azacitidine + venetoclax in patients with R/R or newly diagnosed AML
Courtney DiNardo, MD, provides opinion on current treatment strategies for elderly AML patients
OMNIVERSE: safety and tolerability of oral azacitidine plus venetoclax in patients with AML
Is enasidenib plus azacitidine better than with azacitidine alone for AML patients?
Dr. Winer Discusses the FDA Approval of Ivosidenib in AML
QUAZAR AML-001: oral azacitidine as maintenance therapy in AML
Meet leukemia oncologist Courtney DiNardo, M.D.
Oral therapies in the future of AML treatment
